Explore the Agenda

4:00 pm Introducing Myriad’s Ultra-Sensitive Tumor Informed MRD Assay

SVP, Myriad Genetics, Inc.

Join us for a hosted learning and networking engager in partnership with Myriad Genetics 


Join this deep-dive session to understand how ultra-sensitive, tumor-informed MRD  testing is being applied across real clinical and development settings. Hear how  leading experts are translating MRD data into actionable decisions across patient  management, trial design, and therapeutic development. Walk away with a clear view of where MRD delivers value today and how to apply it across your own programs.



Register your interest* to attend

*Attendance subject to availability and partner approval. For T&Cs please visit website.